跳至主要内容
临床试验/ACTRN12618000811202
ACTRN12618000811202进行中(未招募)3 期

Targeted thromboprophylaxis in ambulatory patients receiving anticancer therapies for lung or gastrointestinal cancers: an investigator-initiated, open-label, multicentre, randomised, phase 3 trial (TARGET-TP)

Peter MacCallum Cancer Centre0 个研究点目标入组 328 人开始时间: 2018年5月11日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
328

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1.Patient is 18 years of age or older
  • 2.Patient has a confirmed histological diagnosis of any gastrointestinal or lung cancer
  • 3.Patient is newly diagnosed treatment-naïve or is previously treated with newly relapsed or progressive disease
  • 4.Patient is being considered for, but has not commenced anticancer therapy including chemotherapy and/or radiotherapy and/or immunotherapy and/or targeted therapies, within neoadjuvant, adjuvant, curative, or palliative treatment settings
  • 5.Patient has expected life expectancy of at least six months, as estimated by their treating clinician
  • 6.Patient has provided written confirmation of informed consent on participant information and consent form

排除标准

  • 1.Patients who have already commenced anticancer therapy
  • 2.Patients with a clinical indication for therapeutic anticoagulation (antiplatelet agents such as clopidogrel and aspirin are permitted)
  • 3.Patients with a contraindication to anticoagulation and/or specifically low molecular weight heparin
  • 4.Cancer diagnosis other than those specified in inclusion criteria

研究者

发起方
Peter MacCallum Cancer Centre

相似试验